Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mitsubishi UFJ Financial Group has lodged a notice indicating it has ceased to be a substantial holder in Mayne Pharma Group, following a series of trades in the company’s fully paid ordinary shares during January 2026. The transactions, executed through entities controlled by First Sentier Group and Morgan Stanley, reflect ongoing portfolio adjustments among major institutional investors and may slightly alter the ownership profile and liquidity dynamics of Mayne Pharma’s stock without signalling any change to the company’s underlying operations.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australian pharmaceutical company that develops and manufactures specialty and generic medicines. It focuses on oral drug delivery technologies and supplies products to both domestic and international markets, serving healthcare providers, pharmacies and patients with a portfolio of branded and non‑branded treatments.
YTD Price Performance: -18.97%
Average Trading Volume: 444,439
Technical Sentiment Signal: Sell
Current Market Cap: A$204.7M
For an in-depth examination of MYX stock, go to TipRanks’ Overview page.